ClinicalTrials.gg
CompletedNCT01338441iQTESTUpdated Sep 15, 2011

Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples

A Phase 1 interventional study of Erythromycin and Placebo in Cardiology: RR / QT, sponsored by Ectycell SASU. Completed at 1 site in France. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-15.

Sponsored by Ectycell SASU · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The study main objective is to assess the changes in the ventricular repolarization (measure by the delta QTcf) after drug induced stimulation, compare to placebo, in order to identify subjects with extreme responses and collecting their skin and blood samples.

Read the detailed description

An ECG is performed after a dose of sotalol on about 100 healthy subjects in order to identify about 20 extreme responders (10 high responders and 10 non responders) assessed as Delta QTcf compare to baseline. The ECG will be measured and the delta QTcf will be calculated on the 20 selected subjects in a second part of the clinical trial, cross over erythromycin/placebo.

02

Conditions studied

  • Cardiology: RR / QT

Keywords

  • Drug induced QT prolongation
03

In context

Lead sponsor

This is the only study on the registry with Ectycell SASU as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • 18 to 40 years of age
  • Caucasian origin
  • 19 to 29 kg/m²
  • obtained
  • National Health Security Number
  • Eligible for Phase I as mentioned in the national registry of healthy volunteers
  • For woman: use of an effective method

Non Inclusion Criteria:

  • Asthma
  • Heart Rate \< 50 bpm
  • Hypotension with systolic blood pressure\< 100 mm Hg.
  • atrioventricular block (PR interval > 200 ms)
  • Known Chronic illness (hepatic, renal or cardiac impairment, etc..)
  • Raynaud's phenomenon
  • Drug known to prolong (http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm) in the last 7 days.
  • All chronic treatments are forbidden exceptive : oral contraceptives, paracetamol, vitamins and comfort treatment that do not prolong the QT
  • Known family or individual past history of QT prolongation or unexplained syncope
  • (QTcF) > 450 ms
  • QRS interval non assessable on at rest or bundle-branch block, QRS > 100 ms
  • Allergy to macrolide type antibiotics
  • Known allergy to sotalol or lidocaine
  • Positive blood pregnancy test (Inclusion visit)
  • Known abnormal haemostasis
  • Kaliemia\< 3.5 mmol/L
  • Magnesemia\< 0,7 mmol/L
  • Under exclusion period or participating to another clinical trial on a new medicinal product
  • Creatinin clearance \< 80 ml/min (Cockroft and Gault formula)
  • -ALT >3x upper normal limit
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Erythromycin

    Drug: Erythromycin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 4mg/Kg, IV during 20 min once

  • DrugPlacebo

    4mg/Kg, IV during 20 min once

06

What researchers measure

Primary outcomes

  1. Prolongation of cardiac QT due to erythromycin compare to Placebo reported as Delta QTcf

    Delta QTcf is measured at H0, H0+20 minutes, and H0+1h20, on groups' erythromycin and placebo. QTcf may be adjusted based on the pharmacokinetic data to ensure time of the plasmatic pick is used.

    Time frame: 1hour and 20 minutes

Secondary outcomes

  1. Comparison Delta QTcf eryhtromycin-sotalol

    compare the effect of erythromycin and sotalol on QT prologation

    Time frame: over 3 hours

  2. Assess the effect of erythromycin Twave morphologie changes

    Analysis of Qwave morphologic changes

    Time frame: 1hour and 20 min

07

Study locations

1 site
  • BIOTRIAL
    Rueil Malmaison, 92500, France
08

References and documents

Publications

  • Stillitano F, Hansen J, Kong CW, Karakikes I, Funck-Brentano C, Geng L, Scott S, Reynier S, Wu M, Valogne Y, Desseaux C, Salem JE, Jeziorowska D, Zahr N, Li R, Iyengar R, Hajjar RJ, Hulot JS. Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. Elife. 2017 Jan 30;6:e19406. doi: 10.7554/eLife.19406. PubMed 28134617 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of May 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2011
First posted
Apr 19, 2011
Start
Mar 2011
Primary completionActual
May 2011
CompletionActual
Aug 2011
Last update
Sep 15, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01338441
Lead sponsor
Ectycell SASU
Collaborators
Pierre and Marie Curie University, Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Apr 19, 2011
Start date
Mar 2011
Primary completion
May 2011
Completion
Aug 2011
Last update
Sep 15, 2011

Study contacts

Jean Sebastien Hulot, MD
study director · University PMCurrie-INSERM

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Erythromycin

Start the discussion